CHChhatar

Chhatar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chhatar has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Arvind Ingle

    Laboratory Animal Facility, Animal Oncology Group, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre Navi Mumbai, India

    1 shared publication
  • Astha Sharma

    Medicinal Chemistry and Cell Biology Laboratory Department of Chemical Sciences Tata Institute of Fundamental Research Homi Bhabha Road Mumbai Maharashtra 400005 India

    1 shared publication
  • Jyoti Kode

    Kode Lab, Tumor Immunology & Immunotherapy Group, Advanced Center for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, India

    1 shared publication
  • Madan Barkume

    Anti-Cancer Drug Screening Facility (ACDSF), ACTREC Tata Memorial Centre, Kharghar Navi Mumbai 410210 India

    1 shared publication
  • Malay Patra

    Tata Institute of Fundamental Research Homi Bhabha Road

    1 shared publication
  • Manasi Nagare

    Tumor Immunology & Immunotherapy Group (Kode lab) Advanced Centre for Treatment Research & Education in Cancer (ACTREC) Tata Memorial Centre, Kharghar Navi Mumbai 410210 India

    1 shared publication

Latest Publications

  • A Rationally Designed Bimetallic Platinum (II)‐Ferrocene Antitumor Agent Induces Non‐Apoptotic Cell Death and Exertsin VivoEfficacy

    by Shubhankar Gadre, M. Manikandan, Prakash Duari, Sushant Chhatar, Astha Sharma, Subhash Khatri, Jyoti Kode, Madan Barkume, Nirmal Kumar Kasinathan, Manasi Nagare, et al.

    Despite phenomenal clinical success, the efficacy of platinum anticancer drugs is often compromised due to inherent and acquired drug resistant phenotypes in cancers. To circumvent this issue, we designed two heterobimetallic platinum (II)‐ferrocene hybrids that display multi‐pronged anticancer action. In cancer cells, our best compound,2, platinates DNA, produces reactive oxygen species, and has nucleus, mitochondria, and endoplasmic reticulum as potential targets. The multi‐modal mechanism of action of these hybrid agents lead to non‐apoptotic cell death induction which enables circumventing apoptosis resistance and significant improvement in platinum cross resistance profile. Finally, in addition to describing detail mechanistic insights, we also assessed its stability in plasma and demonstrate anticancer efficacy in an in vivo A2780 xenograft model. Strikingly, compared to oxaliplatin, our compound displays better tolerability, safety profile and efficacy in vivo.